|
AP2016009222A0
(en)
|
2013-11-04 |
2016-05-31 |
Glenmark Pharmaceuticals Sa |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
CN109071632B
(zh)
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2018054484A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Biontech Ag |
Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
|
|
EP3576765B1
(en)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
JP7556687B2
(ja)
|
2017-02-24 |
2024-09-26 |
中外製薬株式会社 |
薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
|
|
EP3366704A1
(en)
|
2017-02-28 |
2018-08-29 |
Affimed GmbH |
Antibodies specific for mmp1/hla-a2 complex
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
US11319371B2
(en)
*
|
2017-06-05 |
2022-05-03 |
Numab Therapeutics AG |
Anti-CD3 antibodies
|
|
US11472880B2
(en)
|
2017-08-14 |
2022-10-18 |
Morphosys Ag |
Humanized antibodies for CD3
|
|
KR101973060B1
(ko)
*
|
2017-10-20 |
2019-04-26 |
주식회사 녹십자 |
항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
EP3502140A1
(en)
*
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
CN120399075A
(zh)
*
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
BR112020023508A2
(pt)
*
|
2018-05-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Anticorpos anti-cd3 e usos dos mesmos
|
|
WO2020023553A1
(en)
*
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
MX2021002165A
(es)
|
2018-08-23 |
2021-07-16 |
Regeneron Pharma |
Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
MY204320A
(en)
|
2019-03-29 |
2024-08-22 |
Mogam Inst Biomedical Res |
Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
PE20230389A1
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
|
|
WO2022175255A2
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
TW202330594A
(zh)
|
2021-09-29 |
2023-08-01 |
美商莫德斯醫療公司 |
抗原結合多肽、抗原結合多肽複合物及其使用方法
|
|
CN116375867B
(zh)
|
2021-12-31 |
2026-05-29 |
康源博创生物科技(北京)有限公司 |
抗gprc5d抗体及其应用
|
|
CN116375868A
(zh)
*
|
2021-12-31 |
2023-07-04 |
康源博创生物科技(北京)有限公司 |
一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
WO2024152963A1
(zh)
*
|
2023-01-18 |
2024-07-25 |
贝达药业股份有限公司 |
抗cd3的人源化抗体及其应用
|
|
WO2025224084A1
(en)
|
2024-04-22 |
2025-10-30 |
Engimmune Therapeutics Ag |
Proteins comprising t cell receptor constant domains
|
|
WO2026125496A1
(en)
|
2024-12-10 |
2026-06-18 |
Engimmune Therapeutics Ag |
Multifunctional molecules comprising soluble tcr fragments and uses thereof
|